Drug Trial Radar · NCT01208181
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
Last checked: Nov 19, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,404
Actual
Start
Sep 27, 2010
Primary completion
Jun 9, 2014
Study completion Jul 29, 2014
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part (6 weeks duration for each part), randomized, double-blind, placebo-controlled study in participants with rheumatoid arthritis. The hypothesis is that etoricoxib (60 mg and 90 mg) administration will demonstrate superior efficacy compared to placebo after 6 weeks of treatment, as measured by the greater mean improvement from baseline in the Disease Activity Score C-Reactive Protein (DAS-28 CRP), and by the greater mean improvement in Patient Global Assessment of Pain (PGAP) from baseline over 6 weeks of treatment. Additionally, the added benefit of increasing the dose of etoricoxib from 60 mg to 90 mg will be assessed in the second part of the study.
Conditions
- Arthritis, Rheumatoid
Interventions
Etoricoxib 60 mgDrug
One tablet orally once daily for 6 weeks.
Etoricoxib 90 mgDrug
One tablet orally once daily for 6 weeks.
Placebo to Etoricoxib 60 mgDrug
One tablet orally once daily for 6 weeks.
Placebo to Etoricoxib 90 mgDrug
One tablet orally once daily for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-Weighted Average Change From Baseline in DAS28-CRP in Part 1 (Etoricoxib vs. Placebo)Time frame: Baseline and Week 6
- Time-Weighted Average Change From Baseline in Patient Global Assessment of Pain in Part 1 (Etoricoxib vs. Placebo)Time frame: Baseline and Week 6
- Percentage of Participants Who Experienced at Least One Adverse Event (AE)Time frame: Up to 112 days
- Percentage of Participants Who Discontinued Study Drug Due to an AETime frame: Up to Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.